Radioactive 'smart bomb' tested against stubborn blood cancer
NCT ID NCT06888323
Summary
This early-stage trial is testing whether a radioactive antibody called lintuzumab-Ac225 can help control advanced myelodysplastic syndrome (MDS) that hasn't responded to standard treatments. The treatment works by attaching to cancer cells and delivering radiation directly to them. The study aims to find the safest dose and see if it helps patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.